Theravance Biopharma TBPH Debt-to-equity

Debt-to-equity at other companies

Gyre Therapeutics, Inc.GYRE

0×0.0×

Rigel PharmaceuticalsRIGL

0.2×+0.1×

LQD

Liquidia CorporationLQDA

0.1×-0.1×

Royalty PharmaRPRX

0.9×+0.1×

Zevra Therapeutics, Inc.ZVRA

0×-0.5×

Aurinia PharmaceuticalsAUPH

0.1×-0.2×

FAQ

What is Theravance Biopharma's debt-to-equity?

Theravance Biopharma (TBPH) reported debt-to-equity of 0.1× in Q1 2026.

How has Theravance Biopharma's debt-to-equity changed year-over-year?

Theravance Biopharma's debt-to-equity decreased by 51.9% year-over-year, from 0.3× to 0.1×.

What is the long-term trend for Theravance Biopharma's debt-to-equity?

Over 3 years (2022 to 2025), Theravance Biopharma's debt-to-equity has grown at a 6.8% compound annual growth rate (CAGR), from 0.1× to 0.1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.